Enlivex, a pharma company, announced it has closed a $21 million debt financing agreement to expand its RAIN token treasury, the governance token of the decentralized prediction market.
On Monday, the company announced that it closed the $21 million convertible debt deal with The Lind Partners, a New York-based investor. Convertible debt is a loan that can be converted into company shares rather than repaid in cash. Lind Partners can convert the debt into Enlivex shares at a fixed price of $2.60 per share, which is well above the current stock price.
Buying RAIN at a steep discount
As part of the announcement, Enlivex said it used $10 million from the debt to purchase about 3 billion tokens for $0.0033 per token. This price represents a 62% discount to the token’s closing price on March 22, 2026.
The Rain Foundation also extended Enlivex’s option to buy up to an additional 272.1 billion RAIN tokens at the same discounted price of $0.0033 per token from the deadline of November 30, 2026, to December 31, 2027.
Enlivex is building a prediction markets treasury strategy with its main biotech business. The company holds RAIN tokens as part of its treasury, betting that the growth of prediction markets will create value for shareholders.
Market reacts to biotech companies adding crypto holdings
Following the news, the RAIN token rose as high as 7% before settling near $0.0088. Enlivex shares came down at $1.10 but gained about 4.5% in after-hours trading, making Enlivex one of the businesses adding cryptocurrency holdings to their portfolios to increase shareholder value and attract new investors.
This move shows how some traditional biotech companies are adding cryptocurrency holdings to their balance sheets to potentially boost shareholder value and attract new investors.
RAIN is the core token governing the Rain Protocol, a decentralized prediction market built on the Arbitrum network.
Prediction markets are currently exploding, with trading volumes jumping over 1,200% in the last year alone. By locking in these tokens at a fraction of their market value, Enlivex Executive Chairman Shai Novik believes the company is creating substantial shareholder value through its treasury operations.
Betting on its own stock
Enlivex’s Board approved a $20 million share buyback program. By removing shares from the open market, the company aims to enhance its shareholder value.
This is happening as Enlivex prepares to voluntarily delist from the Tel Aviv Stock Exchange to focus only on a Nasdaq listing, a move designed to streamline operations as it heads toward a major Phase 2b clinical trial for its knee osteoarthritis treatment, Allocetraâ„¢.
